

# Chapter 219

## Topical Antifungal Agents

Whitney A. High & James E. Fitzpatrick

### REFERENCES

1. Borgers M: Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. *Rev Infect Dis* 2:520, 1980 [PMID: 7003674]
2. Croxtall JD, Plosker GL: Sertaconazole: A review of its use in the management of superficial mycoses in dermatology and gynaecology. *Drugs* 69:339-359, 2009
3. Centikaya Z et al: Antifungal susceptibilities of dermatophytic agents isolated from clinical specimens. *Eur J Dermatol* 15:258, 2005
4. Esteban A, Abarca ML, Cabanes FJ: Comparison of disk diffusion method and broth microdilution method for antifungal susceptibility testing of dermatophytes. *Med Mycol* 43:61, 2005 [PMID: 15712608]
5. Karaca N, Koc AN: In vitro susceptibility testing of dermatophytes: comparison of disk diffusion and reference broth dilution methods. *Diagn Microbiol Infect Dis* 48:259, 2004 [PMID: 15062918]
6. Rosen T, Schell BJ, Orengo I: Anti-inflammatory activity of antifungal preparations. *Int J Dermatol* 36:788, 1997 [PMID: 9372359]
7. Hegemann L et al: Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. *J Invest Dermatol* 100:343, 1993 [PMID: 8440921]
8. Bremm KD, Plempel M: Modulation of leukotriene metabolism from human polymorphonuclear granulocytes by bifonazole. *Mycoses* 34:41, 1991 [PMID: 1922187]
9. van Cutsem J et al: The anti-inflammatory effects of ketoconazole. A comparative study with hydrocortisone acetate in a model using living and killed *Staphylococcus aureus* on the skin of guinea-pigs. *J Am Acad Dermatol* 25:257, 1991
10. Jones BM et al: Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. *Antimicrob Agents Chemother* 33:970, 1989 [PMID: 2764547]
11. Holt RJ: Topical pharmacology of imidazole antifungals. *J Cutan Pathol* 3:45, 1976 [PMID: 945306]
12. Franz TJ, Lehman P: Percutaneous absorption of sulconazole nitrate in humans. *J Pharm Sci* 77:489, 1998
13. Susilo R et al: Rate and extent of percutaneous absorption of sertaconazole nitrate after topical administration. *Arzneimittelforschung* 55:338, 2005 [PMID: 16032974]
14. Pitcher DG, Noble WC, Seville RH: Treatment of erythrasma with miconazole. *Clin Exp Dermatol* 4:453, 1979 [PMID: 535173]
15. Nolting S, Strauss WB: Treatment of impetigo and ecthyma. A comparison of sulconazole with miconazole. *Int J Dermatol* 27:716, 1988 [PMID: 3069760]
16. Tanenbaum L et al: Sulconazole nitrate cream 1% for treating tinea cruris and corporis. *Cutis* 44:344, 1989 [PMID: 2805811]
17. Tanenbaum L et al: Sulconazole nitrate 1.0% cream: A comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. *Cutis* 30:105, 1982 [PMID: 6749440]
18. Gupta AK et al: An overview of topical antifungal therapy in dermatomycoses. A North American perspective. *Drugs* 55:645, 1998 [PMID: 9585862]
19. Weinstein A, Berman B: Topical treatment of common superficial tinea infections. *Am Fam Physician* 65:2095, 2002 [PMID: 12046779]
20. Lotrisone package insert. Kenilworth, NJ, Schering Corp., 1994
21. Katz HI et al: SCH 370 (clotrimazole-betamethasone dipropionate) cream in patients with tinea cruris or tinea corporis. *Cutis* 34:183, 1984 [PMID: 6383734]
22. Barkey WF: Striae and persistent tinea corporis related to prolonged use of betamethasone dipropionate 0.05%; cream/clotrimazole 1%; cream (Lotrisone cream). *J Am Acad Dermatol* 17:518, 1987 [PMID: 3655035]
23. Smith EB et al: Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis. *J Am Acad Dermatol* 26:125, 1992 [PMID: 1732321]

24. Alston SJ, Cohen BA, Braun M: Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. *Pediatrics* **111**:201, 2003 [PMID: 12509578]
25. Greenberg HL et al: Clotrimazole/betamethasone dipropionate: A review of costs and complications in the treatment of common cutaneous fungal infections. *Pediatr Dermatol* **19**:78, 2002 [PMID: 11860579]
26. Railan D et al: Pediatricians who prescribe clotrimazole-betamethasone dipropionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug's potency. *Dermatol Online J* **8**:3, 2002 [PMID: 12546758]
27. Vasquez E, Pollak R, Benedetti E: Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. *Clin Transplant* **15**:95, 2001 [PMID: 11264634]
28. Pelletier R et al: Emergence of resistance of *Candida albicans* to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations. *J Clin Microbiol* **38**:1563, 2000 [PMID: 10747144]
29. Carrilo-Munoz AJ, Tur C, Torres J: In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the *Candida* genus. *J Antimicrob Chemother* **37**:815, 1996 [PMID: 8722548]
30. Petranyi G, Ryder NS, Stutz A: Allylamine derivatives: New class of synthetic antifungal agents inhibiting fungal squalene epoxidase. *Science* **224**:1239, 1984 [PMID: 6547247]
31. Nahm WK, Orengo I, Rosen T: The antifungal agent butenafine manifests anti-inflammatory activity in vivo. *J Am Acad Dermatol* **41**:203, 1999 [PMID: 10426889]
32. Steinhilber D: Effects of novel antifungal azole derivatives on the 5-lipoxygenase and cyclooxygenase pathways. *Drug Res* **40**:1260, 1990 [PMID: 2128178]
33. Choi TS et al: Effect of naftifine on neutrophil adhesion. *Skin Pharmacol* **9**:190, 1996 [PMID: 8737916]
34. Burkhart CG, Burkhart CN, Isham N: Synergistic antimicrobial activity by combining an allylamine with benzoyl peroxide with expanded coverage against yeast and bacterial species. *Br J Dermatol* **154**:341, 2006 [PMID: 16433807]
35. Jones TC: Treatment of dermatomycoses with topically applied allylamines: naftifine and terbinafine. *J Dermatol Treat* **1**:29, 1990
36. Arika T, Hase T, Yokoo M: Anti-*Trichophyton mentagrophytes* activity and percutaneous permeation of butenafine in guinea pigs. *Antimicrobial Agents Chemother* **37**:363, 1993 [PMID: 8452371]
37. Hill S et al: An investigation of the pharmacokinetics of topical terbinafine (Lamisil) 1% cream. *Br J Dermatol* **127**:396, 1992 [PMID: 1419761]
38. Ciftci E, Guriz H, Aysev AD: Mupirocin vs terbinafine in impetigo. *Indian J Pediatr* **69**:679, 2002 [PMID: 12356219]
39. Leenutaphong V et al: Double-blind study of the efficacy of 1 week topical terbinafine cream compared to 4 weeks miconazole cream in patients with tinea pedis. *J Med Assoc Thai* **82**:1006, 1999 [PMID: 10561963]
40. Patel A: Topical treatment of interdigital tinea pedis: Terbinafine compared with clotrimazole. *Australas J Dermatol* **40**:197, 1999 [PMID: 10570555]
41. Schopf R et al: Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: A randomized, double-blind, multi-centre, 8-week clinical trial. *Mycoses* **42**:415, 1999 [PMID: 10536434]
42. Evans EGV: A comparison of terbinafine (Lamisil) 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks in the treatment of tinea pedis. *Br J Dermatol* **130**:12, 1994 [PMID: 8186134]
43. Korting HC et al: One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. *Med Mycol* **39**:335, 2001 [PMID: 11556763]
44. Evans EG, Seaman RA, James IG: Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. *Br J Dermatol* **130**:83, 1994 [PMID: 8305323]
45. Prices for generic 1% terbinafine cream (30 gm) versus generic clotrimazole 1% cream (30 gm). Bellevue, WA, Drugstore.com, <http://www.drugstore.com>, accessed Mar 1, 2010
46. Bedinghaus JM, Niedfelt MW: Over-the-counter foot remedies. *Am Fam Physician* **64**:791, 2001 [PMID: 11563570]
47. Finlay AY: Skin and nail fungi—Almost beaten. *BMJ* **319**:71, 1999 [PMID: 10398610]
48. Crawford F et al: Topical treatments for fungal infections of the skin and nails of the foot. *Cochrane Database Syst Rev* **18**:CD001434, 2007
49. Morales-Molina JA et al: Possible interaction between topical terbinafine and acenocoumarol. *Ann Pharmacother* **43**:1911, 2009

50. Hazen EL, Brown R: Nystatin. *Ann N Y Acad Sci* **89**:258, 1960 [PMID: 13712559]
51. Gunderson SM et al: In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect. *Antimicrob Agents Chemother* **44**:2887, 2000 [PMID: 10991881]
52. Tubaro E, Bulgini MJ: Cytotoxic and antifungal agents: Their body distribution and tissue affinity. *Nature* **218**:395, 1968 [PMID: 4967743]
53. Marrazzo J: Vulvovaginal candidiasis. *BMJ* **325**:586, 2002 [PMID: 12228137]
54. Young GL, Jewell D: Topical treatment for vaginal candidiasis (thrush) in pregnancy. *Cochrane Database Syst Rev* **4**:CD000225, 2001
55. Cooper SM, Shaw S: Contact allergy to nystatin: An unusual allergen. *Contact Dermatitis* **41**:120, 1999 [PMID: 10445710]
56. Barranco R et al: Type IV hypersensitivity to oral nystatin. *Contact Dermatitis* **45**:60, 2001 [PMID: 11422284]
57. Pichler WJ, Campi P: Allergy to lysozyme/egg white-containing vaginal suppositories. *Ann Allergy* **69**:521, 1992 [PMID: 1471786]
58. Beveridge GW: A comparison of nystatin cream with nystatin/triamcinolone acetonide combination cream in the treatment of candidal inflammation of the flexures. *Curr Med Res Opin* **4**:584, 1977 [PMID: 326494]
59. Stroud JD, Van Dersarl JV: Striae. *Arch Dermatol* **103**:103, 1971 [PMID: 5539499]
60. Fisher AA: Unnecessary addition of ethylenediamine hydrochloride to "generic" nystatin creams. *J Am Acad Dermatol* **20**:129, 1989 [PMID: 2464012]
61. Martin MV, Dinsdale RC: Nystatin-resistance of *Candida albicans* isolates from two cases of oral candidiasis. *Br J Oral Surg* **20**:294, 1982 [PMID: 6760890]
62. Verghese S et al: Prevalence, species distribution and antifungal sensitivity of vaginal yeasts in infertile women. *Indian J Pathol Microbiol* **44**:313, 2001 [PMID: 12024920]
63. Kuriyama T et al: In vitro susceptibility of oral *Candida* to seven antifungal agents. *Oral Microbiol Immunol* **20**:349, 2005 [PMID: 16238594]
64. Alvarez Alvarez ME, Sanchez-Sousa A, Baquero F: A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis. *Rev Esp Quimioter* **11**:295, 1998
65. Abrams BB, Hanel H, Hoehler T: Ciclopirox olamine: A hydroxypyridone antifungal agent. *Clin Dermatol* **9**:471, 1991 [PMID: 1822407]
66. Sakurai K et al: Mode of action of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt. *Chemotherapy* **24**:68, 1978 [PMID: 340169]
67. Gupta AK, Plott T: Ciclopirox: A broad-spectrum antifungal with antibacterial and anti-inflammatory properties. *Int J Dermatol* **43**:3, 2004 [PMID: 15271193]
68. Kokjohn K et al: Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. *Int J Dermatol* **1**:11, 2003
69. Hui X et al: Ciclopirox delivery into the human nail plate. *J Pharm Sci* **93**:2545, 2004 [PMID: 15349963]
70. Loprox Gel (ciclopirox) 0.77% Package insert. Phoenix, AZ, Hoechst Marion Roussel Deutschland GmbH, 2000
71. Stebbins WG et al: Cutaneous adiaspiromycosis: A distinct dermatologic entity associated with *Chrysosporium* species. *J Am Acad Dermatol* **51**:S185, 2004
72. Aly R et al: Ciclopirox gel in the treatment of patients with interdigital tinea pedis. *Int J Dermatol* **42**:29, 2003 [PMID: 14567368]
73. Aly R et al: Ciclopirox gel for seborrheic dermatitis of the scalp. *Int J Dermatol* **42**:19, 2003 [PMID: 12895183]
74. Epstein E: Fungus-free versus disease-free nails. *J Am Acad Dermatol* **50**:151, 2004 [PMID: 14699392]
75. Gupta AK, Fleckman P, Baran R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. *J Am Acad Dermatol* **43**:S70, 2000
76. Avner S, Nir N, Henri T: Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. *J Dermatolog Treat* **16**:327, 2005 [PMID: 16428154]
77. Gupta AK, Lynch LE: Management of onychomycosis: Examining the role of monotherapy and dual, triple, or quadruple therapies. *Cutis* **74**:5, 2004 [PMID: 15287394]
78. Foti C, Diaferio A, Bonamonte D: Allergic contact dermatitis from ciclopirox olamine. *Australas J Dermatol* **42**:145, 2001 [PMID: 11309043]
79. Fuerst JF et al: Comparison between undecylenic acid and tolnaftate in the treatment of tinea pedis. *Cutis* **25**:544, 1980 [PMID: 6991217]
80. Favre B, Ryder NS: Characterization of squalene epoxidase activity from the dermatophyte *Trichophyton rubrum* and its inhibition by terbinafine and other antimycotic agents. *Antimicrob Agents Chemother* **40**:443, 1996 [PMID: 8834895]

81. Tschen EH et al: Comparison of over-the-counter agents for tinea pedis. *Cutis* **23**:696, 1979 [PMID: 378561]
82. Gonzalez Perez R et al: Allergic contact dermatitis from tolnaftate. *Contact Dermatitis* **32**:173, 1995
83. Emmett EA, Marrs JM: Allergic contact dermatitis from tolnaftate. *Arch Dermatol* **108**:98, 1973 [PMID: 4268580]
84. McLain N et al: Undecylenic acid inhibits morphogenesis of *Candida albicans*. *Antimicrob Agents Chemother* **44**:2873, 2000 [PMID: 10991877]
85. Das SK, Adhya S, Banerjee AB: Effect of undecanoic acid on germination of microconidia of wild and undecanoic acid resistance mutant of *Trichophyton rubrum*. *Mycopathologia* **61**:121, 1977 [PMID: 917103]
86. Prince HN: Effect of pH on the antifungal activity of undecylenic acid and its calcium salt. *J Bacteriol* **78**:788, 1959 [PMID: 14434921]
87. Smith EB et al: Topical undecylenic acid in tinea pedis: A new look. *Int J Dermatol* **16**:52, 1977 [PMID: 832943]
88. Shafran LD et al: Topical undecylenic acid for herpes simplex labialis: A multicenter, placebo-controlled trial. *J Infect Dis* **176**:78, 1997 [PMID: 9207352]
89. Leung DT, Sacks SL: Docosanol: A topical antiviral for herpes labialis. *Expert Opin Pharmacother* **5**:2567, 2004 [PMID: 15571473]
90. Anguita JL et al: Allergic contact dermatitis from undecylenic acid in a commercial antifungal nail solution. *Contact Dermatitis* **46**:109, 2002 [PMID: 11918606]
91. Reinel D: Topical treatment of onychomycosis with amorolfine 5% nail lacquer: Comparative efficacy and tolerability of once and twice weekly use. *Dermatology* **184**(Suppl. 1):21, 1992
92. Baran R et al: A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. *Br J Dermatol* **157**:149, 2007
93. Rock FL et al: An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. *Science* **316**:1759, 2007
94. Hui X: In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. *J Pharm Sci* **96**:2622, 2007